

12-08-05

IRW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM100878-P1)

In re Patent Application of: )  
 )  
XIANG-JIN MENG *et al.* )  
 )  
Filed: 03/25/2004 )  
 )  
For: CHIMERIC INFECTIOUS DNA CLONES, )  
CHIMERIC PORCINE CIRCOVIRUSES )  
AND USES THEREOF )

Appln. No.: 10/808,964  
Confirmation No.: 7042  
Customer No.: 000044091  
Group Art Unit: 1648  
Examiner: Shanon A. Foley

TRANSMITTAL LETTER

Dear Sir:

Transmitted in the above-referenced patent application are an Amendment with Appendix and a true copy of an ATCC Deposit Receipt attached thereto. It is believed that no additional fee is required for the amendment to the claims.

Thank you for your attention to this matter.

Respectfully submitted,

VIRGINIA TECH INTELLECTUAL  
PROPERTIES, INC. and IOWA STATE  
UNIVERSITY RESEARCH  
FOUNDATION, INC.

Date: December 7, 2005

By: Anne M. Rosenblum  
Anne M. Rosenblum  
Attorney for Applicants  
Registration No. 30,419

FILING BY EXPRESS MAIL UNDER 37 C.F.R. § 1.110

This correspondence and the accompanying documents identified hereinabove are being deposited with the U.S. Postal Service on December 7, 2005 to be delivered by the "Express Mail Post Office to Addressee" service under Mailing Label Number EQ 077675168 US addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Anne M. Rosenblum  
Anne M. Rosenblum

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM100878-P1)



<i>In re</i> Patent Application of:	)	Appln. No.: 10/808,964
	)	Confirmation No.: 7042
XIANG-JIN MENG <i>et al.</i>	)	Customer No.: 000044091
	)	Group Art Unit: 1648
Filed: 03/25/2004	)	Examiner: Shanon A. Foley
	)	
For: CHIMERIC INFECTIOUS DNA CLONES,	)	
CHIMERIC PORCINE CIRCOVIRUSES	)	
AND USES THEREOF	)	Paper No.: 15

AMENDMENT

Dear Sir:

Responsive to the Official action mailed September 7, 2005, please amend the above-referenced patent application using the below instructions.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

In accord with 37 C.F.R. § 1.121, the amendment to the specification and the amendment to the claims including a complete listing of all pending claims in the application begin on separate sheets. As required, only the claim number and status indicate any canceled claims. The amendment adds no new matter into the application. For the convenience of the Office staff, this amendment is placed in the below Appendix and incorporated herein by reference thereto.

The amended claims are presented to respond directly to the Office action. The specification is amended to correct an obvious typographical or clerical error appearing on page 82, line 14, in that Tables "3-5" should read Tables 13-15. The inadvertent mistake and its correction are readily apparent from the context of the full paragraph as well as Example 24 on page 82 in which the data are presented in Tables 13-15 that follow the example. Appropriate correction of the text is respectfully requested.

At the outset, Applicants gratefully acknowledge that the Examiner has kindly indicated allowable subject matter and held that the prior art does not teach or suggest SEQ ID NO:2 or a nucleotide sequence that is at least 95% homologous to SEQ ID NO:2.

Page 1 of 12